Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment

Wen, Nuan; Zhao, Na; Xu, Huixian; Zhao, Ying; Ma, Jian

doi:10.1007/s11845-021-02837-3

Cited by 7 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inflammation‐regulating role of ITIH4 is conflicting; although some studies showed that ITIH4 served as a pro‐inflammatory cytokine, several evidence has disclosed the anti‐inflammatory properties of ITIH4 in COPD, inflammatory bowel disease, etc. 24 , 39 , 40 , 41 For instance, one previous study finds that ITIH4 is negatively related to IL‐6 in bronchoalveolar lavage fluid of COPD patients. 39 Another study discovers that ITIH4 knockdown induces TNF‐α, IL‐1β, and IL‐6 expression in human placental choriocarcinoma cells.…”

Section: Discussionmentioning

confidence: 99%

Inter‐alpha‐trypsin inhibitor heavy chain 4: A serologic marker relating to disease risk, activity, and treatment outcomes of rheumatoid arthritis

2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Objective Inter‐alpha‐trypsin inhibitor heavy chain 4 (ITIH4) regulates immunity and inflammation, but its clinical role in rheumatoid arthritis (RA) patients remains unclear. Hence, this study was conducted to explore the association of circulating ITIH4 with disease risk, clinical features, inflammatory cytokines, and treatment outcomes of RA. Methods After the enrollment of 93 active RA patients and 50 health controls (HCs), their serum ITIH4 level was analyzed by enzyme‐linked immunosorbent assay (ELISA). For RA patients only, serum ITIH4 level at week (W) 6 and W12 after treatment was also analyzed. Besides, serum tumor necrosis factor‐alpha (TNF‐α), interleukin (IL)‐1β, IL‐6, and IL‐17A at baseline of RA patients were also detected by ELISA. Results ITIH4 was downregulated in RA patients (151.1 (interquartile range (IQR): 106.2–213.5) ng/mL) than in HCs (306.8 (IQR: 238.9–435.1) ng/mL) (p < 0.001). Furthermore, ITIH4 was negatively related to C‐reactive protein (CRP) (rs = −0.358, p < 0.001) and 28‐joint disease activity score using erythrocyte sedimentation rate (DAS28‐ESR) (rs = −0.253, p = 0.014) in RA patients, but not correlated with other clinical features (all p > 0.05). Besides, ITIH4 was negatively linked with TNF‐α (rs = −0.337, p = 0.001), IL‐6 (rs = −0.221, p = 0.033), and IL‐17A (rs = −0.368, p < 0.001) in RA patients, but not correlated with IL‐1β (rs = −0.195, p = 0.061). Moreover, ITIH4 was gradually elevated in RA patients from baseline to W12 after treatment (p < 0.001). Additionally, the increment of ITIH4 at W6 and W12 was linked with treatment response and remission in RA patients (all p < 0.05). Conclusion Circulating ITIH4 possesses clinical utility in monitoring disease risk, inflammation, disease activity, and treatment outcomes of RA.

show abstract

Section: Discussionmentioning

confidence: 99%

Inter‐alpha‐trypsin inhibitor heavy chain 4: A serologic marker relating to disease risk, activity, and treatment outcomes of rheumatoid arthritis

2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…As a novel anti‐inflammatory factor, the dysregulation of ITIH4 has been revealed in various diseases, such as autoimmune, cardiovascular, and cerebrovascular diseases 17,23–26 . For instance, serum ITIH4 is reduced in inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) patients compared to HCs 23,24 .…”

Section: Discussionmentioning

confidence: 99%

“…Regarding the association between ITIH4 with clinical characteristics and inflammatory cytokines, several studies have explored this aspect in patients with autoimmune diseases 23,24 . Whereas the correlation between ITIH4 with clinical properties and inflammation in sepsis patients still should be investigated.…”

Section: Discussionmentioning

confidence: 99%

“…As a novel anti‐inflammatory factor, the dysregulation of ITIH4 has been revealed in various diseases, such as autoimmune, cardiovascular, and cerebrovascular diseases. 17 , 23 , 24 , 25 , 26 For instance, serum ITIH4 is reduced in inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) patients compared to HCs. 23 , 24 Meanwhile, a previous study claims that serum ITIH4 may be a potential biomarker for coronary heart disease (CHD) patients since it is decreased in patients with acute cardiovascular events compared to patients without those events.…”

Section: Discussionmentioning

confidence: 99%

“… 17 , 23 , 24 , 25 , 26 For instance, serum ITIH4 is reduced in inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) patients compared to HCs. 23 , 24 Meanwhile, a previous study claims that serum ITIH4 may be a potential biomarker for coronary heart disease (CHD) patients since it is decreased in patients with acute cardiovascular events compared to patients without those events. 25 In addition, serum ITIH4 is also reduced in acute ischemic stroke patients compared to HCs.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Longitudinal change of serum inter‐alpha‐trypsin inhibitor heavy chain H4, and its correlation with inflammation, multiorgan injury, and death risk in sepsis

Zhao

Guo²,

et al. 2023

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background: Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4) inhibits infectioninduced inflammation and multiorgan injury through several methods. The present study aimed to estimate the association of serum ITIH4 with inflammatory cytokines, multiorgan injury, and death risk in sepsis patients.Methods: Serum samples were collected to detect ITIH4 by enzyme-linked immunosorbent assay in 127 sepsis patients at admission (baseline), day (D)1, D3, and D7 after admission, as well as in 30 healthy controls (HCs). Additionally, 28-day mortality was recorded in sepsis patients. Results: ITIH4 was reduced in sepsis patients versus HCs (median [interquartile

show abstract

Usability of serum inter-α-trypsin inhibitor heavy chain 4 as a biomarker for assessing severity and predicting functional outcome after human aneurysmal subarachnoid hemorrhage: A prospective observational cohort study at a single institution

Tian,

Wang,

Zhong

et al. 2024

Clinica Chimica Acta

View full text Add to dashboard Cite

Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment

Cited by 7 publications

References 25 publications

Inter‐alpha‐trypsin inhibitor heavy chain 4: A serologic marker relating to disease risk, activity, and treatment outcomes of rheumatoid arthritis

Inter‐alpha‐trypsin inhibitor heavy chain 4: A serologic marker relating to disease risk, activity, and treatment outcomes of rheumatoid arthritis

Longitudinal change of serum inter‐alpha‐trypsin inhibitor heavy chain H4, and its correlation with inflammation, multiorgan injury, and death risk in sepsis

Usability of serum inter-α-trypsin inhibitor heavy chain 4 as a biomarker for assessing severity and predicting functional outcome after human aneurysmal subarachnoid hemorrhage: A prospective observational cohort study at a single institution

Contact Info

Product

Resources

About